Welcome to our dedicated page for Tharimmune news (Ticker: THAR), a resource for investors and traders seeking the latest updates and insights on Tharimmune stock.
Tharimmune, Inc. (NASDAQ: THAR) generates news across two distinct but connected areas: clinical-stage biotechnology and digital asset treasury activities centered on Canton Coin and the Canton Network. Company press releases highlight progress for its lead asset TH104, an investigational nalmefene buccal film being advanced via a 505(b)(2) NDA pathway as a prophylactic countermeasure against respiratory and nervous system depression from high-potency opioids in military personnel and chemical incident responders.
News coverage frequently includes regulatory milestones such as positive feedback from the U.S. Food and Drug Administration (FDA) on Tharimmune’s pharmacokinetic modeling plan for TH104 and confirmation that no additional clinical trials appear necessary for a specified indication. Updates also address intellectual property developments, including patents granted or allowed in multiple countries for the TH104 transmucosal film technology, and corporate developments such as board appointments and leadership changes aligned with the company’s national security and addiction-related focus.
Tharimmune also issues news about its broader pipeline, including TH023, a novel oral monoclonal antibody program targeting TNF-alpha, and an early-stage multispecific biologic platform using its proprietary EpiClick™ Technology for solid tumors. These releases describe preclinical data, planned development steps, and strategic licensing arrangements.
On the digital asset side, Tharimmune’s news flow covers private placements, securities purchase agreements, and treasury strategy updates related to Canton Coin. The company reports on transactions led by institutional investors, its intention to operate as a Super Validator on the Canton Network, and commentary on initiatives such as the tokenization of U.S. Treasury securities on that network. Investors following THAR news can therefore expect a mix of clinical, regulatory, intellectual property, governance, financing, and blockchain-related announcements. Bookmarking this page provides a single stream of these updates as they are released.
Tharimmune (NASDAQ: THAR) closed a private placement on Nov 6, 2025, raising approximately $545 million gross by selling common shares (or pre-funded warrants) at $3.075 per share. Net proceeds are intended to acquire Canton Coin (CC), fund operation as a Super Validator, run additional validators, and support application development on the Canton Network, with remaining proceeds for working capital and general corporate purposes.
Led by DRW and Liberty City Ventures, investors include ARK Invest, Polychain, Kraken, Broadridge, Tradeweb Markets, and the Canton Foundation, making Tharimmune the first public company supported by the Canton Foundation.
Tharimmune (NASDAQ: THAR) announced a private placement to raise approximately $540 million at $3.075 per share, led by DRW and Liberty City Ventures with participation from institutional investors including ARK Invest, Kraken, Polychain, and the Canton Foundation. The proceeds are intended to buy Canton Coin (CC), fund a diversified digital-asset-treasury (DAT) strategy, and support working capital. Tharimmune plans to operate as a Super Validator and run additional validators to generate CC rewards and to invest in Canton Network applications. Closing is expected on or about November 6, 2025, subject to customary conditions.
Management appointed Mark Wendland as CEO for the digital asset treasury strategy and Mark Toomey as President; the biotech business remains under existing management. Canton reported >500,000 daily transactions as of Sept 30, 2025.
Tharimmune (Nasdaq:THAR) announced positive pharmacokinetic simulation results for TH104, its buccal film formulation of nalmefene, designed as a prophylactic treatment against respiratory depression from fentanyl and ultrapotent opioids.
The simulation analysis revealed that TH104 achieves protective effects within 30 minutes post-dose and maintains protection for approximately 24 hours, potentially offering superior duration compared to existing treatments like naloxone. The non-injectable buccal delivery system provides rapid absorption and convenient administration for first responders and military personnel.
Notably, the FDA previously indicated that no additional clinical trials appear necessary before a 505(b)(2) New Drug Application submission, streamlining the path to potential approval.
Tharimmune (Nasdaq:THAR) has secured significant global patent protection for TH-104, its novel transmucosal film technology, extending coverage until at least 2040. The patents, granted in Japan, Mexico, Australia, and the United States, cover a unique method for administering nalmefene via a single-layer, mucoadhesive film.
The FDA has provided positive feedback on TH-104's NDA pathway, confirming that a 505(b)(2) submission is viable for preventing respiratory and CNS distress, with no additional clinical trials required for military and first responder use against weaponized opioids. The drug features a longer half-life compared to existing alternatives like Narcan®, potentially providing sustained protection in high-risk environments.
Tharimmune (NASDAQ:THAR) has appointed renowned philanthropist Nancy Davis to its Board of Directors. Davis, founder of Race to Erase MS and Cure Addiction Now (CAN), brings extensive experience in patient advocacy and medical research advancement. Her organization Race to Erase MS has raised over $56 million for MS research through its "Center Without Walls" program, contributing to the development of FDA-approved therapies like Ocrevus®, Briumvi®, and Kesimpta®.
Davis's appointment is particularly significant as Tharimmune advances TH104, their investigational product being developed as a countermeasure against weaponized fentanyl for military use and chemical incident responders, with potential applications in addressing the opioid crisis. Her experience with CAN, which focuses on innovative addiction treatment research, aligns with Tharimmune's mission to develop breakthrough therapies for inflammation, immunology, and critical unmet medical needs.
Tharimmune (NASDAQ:THAR) provided a comprehensive corporate update highlighting two key programs and recent financing. The company raised $5.47 million in equity financing during Q2/Q3 2025.
Their lead asset TH104, a buccal film formulation of nalmefene, is being developed as a critical national security solution against weaponized fentanyl. The FDA has confirmed no additional clinical trials are needed before NDA submission via the 505(b)(2) pathway. The drug offers advantages over existing solutions with a longer half-life of 8-11 hours.
The company's second program, TH023, is developing an oral formulation of infliximab (TNF-alpha inhibitor) for inflammatory conditions. Preclinical studies have demonstrated successful oral delivery achieving significant therapeutic levels. The company plans to initiate first-in-human trials within 12 months.
Tharimmune (NASDAQ:THAR), a clinical-stage biotech company, has announced the pricing of a $1.74 million registered direct public offering of common stock and warrants. The offering includes 414,331 shares of common stock and 559,910 pre-funded warrants, along with 974,241 warrants to acquire common stock at an exercise price of $1.66 per share.
The units, comprising one share of common stock or pre-funded warrant and a common warrant, are priced at $1.786 per unit. President Street Global, LLC serves as the exclusive placement agent. The offering is expected to close around July 25, 2025, with proceeds intended for working capital and general corporate purposes.